CAS: 1439399-58-2; 2-(Pyridin-2-yl)-N-(5-(4-(6-(2-(3-(Trifluoromethoxy)Phenyl)Acetamido)Pyridazin-3-yl)Butyl)-1,3,4-Thiadiazol-2-yl)Acetamide

上下游产品

N-(6-(4-(5-Amino-1,3,4-Thiadiazol-2-yl)Butyl)Pyridazin-3-yl)-2-(3-Trifluoromethoxyphenyl)Acetamide 1439399-45-7
N-(6-(4-Cyanobutyl)Pyridazin-3-yl)-2-(3-Trifluoromethoxyphenyl)Acetamide 1439400-48-2
N-(6-Chloropyridazin-3-yl)-2-(3-(Trifluoromethoxy)Phenyl)Acetamide 1439400-46-0

📜N-(6-(4-Cyanobutyl)Pyridazin-3-yl)-2-(3-Trifluoromethoxyphenyl)Acetamide置于1-丙基磷酸酐,三乙胺,三氟乙酸体系中,用 N,N-二甲基甲酰胺 用作溶剂,化学反应 6.0H,反应生成Kga和gac抑制剂(Cb-839)
参考文献: Heterocyclic Inhibitors Of Glutaminase[fr] Inhibiteurs Hétérocycliques De Glutaminase
标题: Heterocyclic Inhibitors Of Glutaminase[fr] Inhibiteurs Hétérocycliques De Glutaminase
摘要:本发明涉及式(I)定义的杂环化合物及其药物制剂.本发明进一步涉及使用本发明的杂环化合物治疗癌症,免疫性或神经疾病的方法.

专利信息

专利号:US-10975048-B2
优先权日:2015-12-14
标题 :Composition of 1,3,4-selenadiazole containing compounds with pharmacological activity
发明人：RUAN BENFANG HELEN; RUAN JENNIFER JIN
权利人:HANGZHOU JENNIFER BIOTECH CO LTD
摘要:The invention belongs to the field of biomedical research involving the 1,3,4-selenyldiazo derivatives that have cell protective activity. Because there are not so many heterocyclic selenium compounds, we synthesized a new type of selenium analog of BPTES. As the isoacceptor of BPTES, the compounds have antitumor activity, anti-oxidation and cell protection function. Currently many drugs contain the thiodiazo motif, so synthesis of selenyldiazo functional group could further optimize these drugs and are important in new drug development and application.

专利号:WO-2023144235-A1
优先权日:2022-01-27
标 题 :Methods for monitoring and treating warburg effect in patients with pi3k-related disorders
发明人：CANAUD GUILLAUME; LADRAA SOPHIA
权利人:INST NAT SANTE RECH MED; ASSIST PUBLIQUE HOPITAUX PARIS APHP; CENTRE NAT RECH SCIENT; UNIV PARIS CITE
摘要:Using a unique tool of PROS, they demonstrate that PIK3CA mutation leads to GLUT4 membrane accumulation with a negative feedback loop on insulin secretion, a burst of liver IGFBP1 synthesis with IGF1 sequestration and low circulating levels. They further show that AKT2 drives a large part of the phenotype. In addition, they demonstrate for the first time that a single PIK3CA mutation induces metabolic reprogramming with the Warburg effect and protein and lipid synthesis—hallmarks of cancer cells—in vitro, in vivo and in patients. They finally show that alpelisib, an approved PIK3CA inhibitor in oncology, is efficient at preventing and improving PIK3CA-adipose tissue overgrowth and reversing metabolomic anomalies in both animal models and patients. Accordingly, the present invention relates to an in vitro method for monitoring the efficiency of a PI3K inhibitor treatment in a subject in need thereof comprising the step of determining the level of at least one metabolite selected in the group consisting of cis-aconitate, succinic acid, 5-methylcytosine, acetyl-carnitine, acetyl-lysine, argininosuccinate, betaine, butyric acid, carnitine, creatine, glucose, glycine, hexanoyl-carnitine, L-fucose, lactate, L-dihydroorotic acid, linolenic acid, nicotinamide N-oxide, palmitoyl-carnitine, panthotenate, pyruvate, quinolinic acid, tryptophan, urate, in a biological sample obtained from the subject.

专利号:CN-115260260-A
优先权日:2021-04-29
标 题 :Selenium-containing ribose compound with KGA inhibitory activity and application of its synthesis method